No, RFK Is Not Banning Antidepressants.
In a Nutshell
RFK Jr. has no plans to ban psychiatric medications. The focus is creating safe, evidence-based tapering protocols for those who want to discontinue, replacing the current practice of abrupt or rapid withdrawal over just weeks. This includes recognizing withdrawal syndromes, distinguishing them from relapse, and building collaboration between clinicians and experienced patients to improve deprescribing practices.
These notes were generated by AI and may contain inaccuracies.
The rumor that RFK Jr. is planning to take away psychiatric medications is described as one of the most absurd claims circulating. There was no discussion at the referenced event about removing medications or access to them. HHS has zero intention of removing any medications. Headlines are making claims that the articles themselves do not support, acknowledging that no banning has been discussed.
Secretary Kennedy is addressing the reality that millions of people are on psychiatric medications and not everyone wants to remain on them long-term. Currently, there are no safe protocols for discontinuation. Doctors lack clinical training in safe tapering despite claims of experience. The goal is to provide safe offramps for those who choose to stop their medications.
The narrative that everyone should come off these medications is explicitly rejected. The position is the opposite: providing people with more options rather than fewer.
Current medical practice often involves abrupt or rapid discontinuation over two to four weeks. This approach is what Kennedy's initiative aims to change by establishing proper clinical protocols for those who wish to taper.
Media response to Secretary Kennedy's announcements has been more positive compared to other recent health policy issues. While clickbait headlines are expected from major news organizations, there has been a notable presence of positive articles.
At the APA annual conference, Dr. Chris Palmer spoke on metabolic psychiatry to a standing-room-only audience. This reflects growing interest among psychiatrists in alternative approaches.
Many psychiatrists are recognizing withdrawal syndromes they previously misdiagnosed. The acknowledgment that symptoms may represent withdrawal rather than relapse is spreading among clinicians who are actively working to advance safer practices.
A doctor raised the challenge of distinguishing between original mental illness symptoms and protracted withdrawal symptoms when there is overlap. Mark Horowitz's research includes methodology for distinguishing withdrawal, such as identifying symptoms never experienced before medication. However, when symptoms mimic pre-medication struggles, differentiation becomes difficult.
Time is considered the best indicator for determining whether symptoms represent withdrawal effects. This process may require years rather than weeks or months, particularly for individuals medicated since childhood who never established a medication-free baseline. Distinguishing between one's natural state, medication effects, and withdrawal effects may not be fully resolvable.
There is a unique opportunity to build collaboration between former patients who have become experts in safe tapering and doctors leading research on hyperbolic tapering, including Mark Horowitz and Yseph Doring. These clinicians acknowledge learning from patient experiences. The current moment allows for bridging metabolic psychiatry approaches with deprescribing protocols.
Keep Mikhaila Peterson in your library
Save the videos and channels worth coming back to, and find them again in one place.
